Filtros de búsqueda

Lista de obras de

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Biomarkers for immune checkpoint inhibitors – Authors' reply

artículo científico publicado en 2014

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

artículo científico publicado en 2014

Circulating haemopoietic and endothelial progenitor cells are decreased in COPD

artículo científico publicado en 2006

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

artículo científico publicado en 2013

Differential levels of soluble endoglin (CD105) in myeloid malignancies

artículo científico publicado en 2003

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

artículo científico publicado en 2015

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

artículo científico publicado en 2013

Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line.

artículo científico publicado en 2006

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

artículo científico publicado en 2007

Epigenetic immunomodulation of hematopoietic malignancies.

artículo científico publicado en 2005

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.

artículo científico publicado en 2010

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.

artículo científico publicado en 2011

Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.

artículo científico publicado en 2007

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

artículo científico publicado en 2017

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.

artículo científico publicado en 2016

Immune checkpoint blockade in malignant mesothelioma

artículo científico

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

artículo científico publicado en 2014

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

artículo científico publicado en 2017

Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain.

artículo científico publicado en 2004

Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukaemia and essential thrombocythaemia

artículo científico publicado en 1998

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

artículo científico publicado en 2010

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

artículo científico publicado en 2011

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

artículo científico publicado en 2014

Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications.

artículo científico publicado en 2004

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

artículo científico publicado en 2013

Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin

artículo científico publicado en 2006

Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.

artículo científico publicado en 2005

New horizons from immunotherapy in malignant pleural mesothelioma.

artículo científico publicado en 2018

Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy

artículo científico publicado en 2020

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

artículo científico publicado en 2017

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

artículo científico publicado en 2017

Soluble angiogenic factors: implications for chronic myeloproliferative disorders

artículo científico publicado en 2002

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

artículo científico publicado en 2014

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.

artículo científico

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

artículo científico

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

artículo científico publicado en 2013